William Schnitz, MD
Rheumatology · Oklahoma City, OKNPI 1629015763
Payments from drug & device makers
Across 796 payments — averaging $363.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$117K
- Novartis$68K
- Pfizer$37K
- Zimmer Biomet$30K
- Amgen$21K
- E.r. Squibb & Sons, L.L.C.$9K
- plus $8K from 25 others
Across 8 payments — averaging $82.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$659
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 101 | $116,566 |
| Novartis | 26 | $68,145 |
| Pfizer | 55 | $36,724 |
| Zimmer Biomet | 8 | $29,617 |
| Amgen(2 entities) | 174 | $21,429 |
| E.r. Squibb & Sons, L.L.C. | 42 | $8,875 |
| AstraZeneca(2 entities) | 51 | $1,381 |
| AbbVie | 52 | $1,195 |
| UCB, Inc. | 60 | $1,067 |
| Johnson & Johnson | 59 | $876 |
| Lilly USA, LLC | 36 | $812 |
| Sandoz | 7 | $492 |
| Sanofi | 25 | $448 |
| Aurinia Pharma U.S., Inc. | 20 | $426 |
| Boehringer Ingelheim | 17 | $418 |
| Genentech USA, Inc. | 23 | $325 |
| Janssen Scientific Affairs, LLC | 2 | $190 |
| Organon | 9 | $145 |
| Fresenius Kabi USA, LLC | 8 | $140 |
| Radius Health, Inc. | 5 | $90 |
| Actelion Pharmaceuticals US, Inc. | 3 | $63 |
| ANI Pharmaceuticals, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Fidia Pharma USA Inc. | 1 | $15 |
| Tersera Therapeutics LLC | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
| Celltrion USA Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $12 |
How this compares
$289,660 in reported general payments places this provider in the 85th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Oklahoma City
- Christine CoddingOklahoma City$2.8M
- Latisha HeinlenOklahoma City$1.9M
- Cristina ArriensOklahoma City$1.8M
- Joan MerrillOklahoma City$1.8M
- Mohammad KhanOklahoma City$999K
- Fahed HamadehOklahoma City$321K
- Michael PickrellOklahoma City$163K
- John GoetzingerOklahoma City$38K
- Judith JamesOklahoma City$18K
- Robert ArthurOklahoma City$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.